Brevan Howard Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Brevan Howard Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.82M	Buy	+31,928	New	+$6.92M	0.06%	228
2026 Q1	–	Sell	-1,238	Closed	-$226K	–	2144
2025 Q4	$226K	Sell	1,238 -6,096	-83%	-$851K	﹤0.01%	1520
2025 Q3	$891K	Sell	7,334 -7,448	-50%	-$839K	﹤0.01%	958
2025 Q2	$1.54M	Buy	+14,782	New	+$1.57M	0.01%	853
2025 Q1	–	Sell	-38,748	Closed	-$3.28M	–	1163
2024 Q4	$3.28M	Buy	38,748 +24,393	+170%	+$2.24M	0.02%	200
2024 Q3	$1.29M	Buy	14,355 +9,573	+200%	+$836K	0.01%	376
2024 Q2	$385K	Buy	+4,782	New	+$354K	﹤0.01%	694

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Brevan Howard Capital Management's AXSM Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 31,928 shares worth $7.82M. The stake represents 0.06% of the portfolio and ranks #228 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in AXSM as recently as Q4 2025.

Brevan Howard Capital Management first reported a position in AXSM in Q2 2024 and has held it in 7 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Brevan Howard Capital Management held 31,928 shares of Axsome Therapeutics worth $7.82M as of Q2 2026.
Axsome Therapeutics was a new Brevan Howard Capital Management position in Q2 2026.
Axsome Therapeutics made up 0.06% of Brevan Howard Capital Management's portfolio in Q2 2026, its #228 holding.
Brevan Howard Capital Management first reported a position in Axsome Therapeutics in Q2 2024 and has held it in 7 quarters since.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.